You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

Tigera, the creator of Project Calico, the most widely adopted container networking and security solution, today announced the addition of significant new functionality to Calico Open Source with the ...

Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Thanks in part to several acquisitions, Pfizer has multiple new growth drivers in its lineup. They include migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven) and cancer ...